Answers are grounded in this paper and cite their sources.
Demonstrates dual-target therapeutic approach in preeclampsia using AI-assisted macitentan derivatives, suggesting potential benefits.
Preeclampsia is a hypertensive disorder of pregnancy marked by angiogenic imbalance and endothelial dysfunction, driven largely by over expression of soluble fms-like tyrosine kinase-1 (sFlt-1) and up-regulation of endothelin-1 (ET-1). Targeting both VEGFR1 and ET-1 receptor could offer a dual-action therapeutic approach. In this study, macitentan, a dual ETA/ ETB antagonist, was used as a scaffold for AI-assisted derivative generation aimed at dual inhibition of these receptors. A comprehensive computational pipeline was applied including molecular docking, pharmacophore modeling, molecular dynamics (MD) simulation, DFT, MM/GBSA, and ADMET analysis. Derivative 24 showed high binding affinity toward VEGFR1 (–7.7 kcal/mol), while Derivative 15 exhibited superior interaction with ET-1 receptor (–9.2 kcal/mol), both outperforming macitentan. MD simulations over 500 ns confirmed complex stability with RMSD stabilization around 0.2–0.3 nm and consistent hydrogen bonds. MM/GBSA binding energies further supported strong receptor interactions (–17.15 kcal/mol for Derivative 24–VEGFR1; –28.72 kcal/mol for Derivative 15–ET-1 receptor). DFT results showed reduced HOMO–LUMO gaps (3.55 eV for Derivative 24; 3.30 eV for Derivative 15), while MEP analysis indicated favorable electrostatic potential for target interaction. Pharmacophore and ADMET profiling revealed improved drug-likeness, high GI absorption, and reduced predicted toxicity. This study presents Derivatives 15 and 24 as promising dual-target leads against preeclampsia-induced endothelial dysfunction. However, experimental validation remains necessary to confirm efficacy and safety before translational application.
No takes yet. Share an insight, caveat, or question.
Sahin et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: